• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form PX14A6G filed by Elevance Health Inc.

    4/14/25 4:40:38 PM ET
    $ELV
    Medical Specialities
    Health Care
    Get the next $ELV alert in real time by email
    PX14A6G 1 o414254px14a6g.htm

     

    Notice of Exempt Solicitation Pursuant to Rule 14a-103

     

    Name of Registrant: Elevance Health Inc (ELV)

     

    Name of person relying on exemption: As You Sow®

     

    Address of persons relying on exemption: 11461 San Pablo Ave, Suite 400, El Cerrito, CA 94530

     

    The attached written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. As You Sow® does not beneficially own more than $5 million of the class of subject securities, and this notice of exempt solicitation is therefore being provided on a voluntary basis.

     

       
     

     

          11461 San Pablo Avenue, Suite 400                    www.asyousow.org

    El Cerrito, CA 94530

       

    BUILDING A SAFE, JUST, AND SUSTAINABLE WORLD SINCE 1992

     

     

     

     

    Elevance Health Inc (ELV)
    Vote Yes: Item #4 – Report on the Effectiveness of the Company's Diversity, Equity, and Inclusion Efforts

    Annual Meeting: May 14, 2025

    CONTACT: Meredith Benton | [email protected]

     

    THE RESOLUTION

     

    Resolved: Shareholders request that Elevance Health Inc report on the effectiveness of diversity, equity, and inclusion efforts to create a workplace where all employees can contribute to the Company’s success. This disclosure should be done at reasonable expense, exclude proprietary information, and provide quantitative metrics for hiring, promotion, and retention rates of employees, including data by gender, race, and ethnicity.

     

    Supporting Statement: Quantitative data is sought so investors can assess and compare the effectiveness of companies’ diversity, equity, and inclusion programs. It is advised that this content be provided through Elevance’s existing sustainability reporting infrastructure. A specific, independent report is not requested.

     

    RATIONALE FOR A YES VOTE

     

    Effective diversity, equity, and inclusion systems do not advantage one group over another, nor do they disadvantage one group over another. Inclusive workplaces have been extensively linked to stronger businesses and financial returns. However, Elevance does not provide quantitative data on the outcomes of its efforts to create a workplace where all employees are able to contribute to the company’s success.

     

    Concerns about discrimination in the American workforce remain very high. What has shifted are the political beliefs about who is experiencing discrimination and how it should be addressed. More than ever, companies need to be able to illustrate that they host a workplace free of discrimination that allows the best talent to thrive.

     

     

    DISCUSSION

     

    Investors are seeking data to understand if Elevance’s workplace is one where all employees can contribute to the Company’s success based on merit. Well managed diversity, equity, and inclusion programs do not place people into roles they don’t deserve; they are focused on ensuring that the bias and discrimination that exist in America1 does not harm the company’s ability to hire, advance, and retain the best possible employees.

     

    _____________________________

     

    1 https://www.pewresearch.org/race-and-ethnicity/2024/06/15/racial-discrimination-shapes-how-black-americans-view-their-progress-and-u-s-institutions-2/; https://academic.oup.com/qje/article-abstract/137/4/1963/6605934; https://academic.oup.com/qje/article-abstract/133/1/191/4060073; https://www.pnas.org/doi/full/10.1073/pnas.1706255114; https://www.shrm.org/topics-tools/news/inclusion-diversity/gender-bias-2024-survey

     

       
     

     

         

    2025 Proxy Memo

    Elevance Health In| Shareholder Proposal Requesting a Report on Effectiveness of Efforts to Create a Meritocratic Workplace

     

     

    Effective human capital management does not advantage one group over another, nor does it disadvantage one group over another.

     

    The U.S. Supreme Court’s June 2023, decision striking down affirmative action in university admissions,2 alongside the January 2025 Executive Order 14173 shifted the political and legal landscape in which companies operate, placing significantly more scrutiny on workplace programs that may advantage specific groups. The Equal Employment Opportunity Commission (EEOC) issued clarifying guidance in March, 2025, reaffirming that Title VII of the Civil Rights Act of 1964 continues to prohibit “discrimination based on protected characteristics such as race and sex.” The EEOC emphasized that disparate treatment of workers, such as exclusion from training, mentorship, or networking events on the basis of a protected characteristic was not allowed. This includes employee affinity groups, and trainings, as well as any employment decision based on the bias of customers.3

     

    Companies’ obligations to workplaces free of discrimination and harassment have not changed. Companies have a legal obligation4 to ensure equal opportunities that cultivate the strongest possible teams — and to refrain from creating workplaces that are hostile, unsafe, discriminatory, or enable harassment.

     

    Investors should seek effective inclusion programs for reasons that go beyond legal considerations. Numerous studies have pointed to the benefits of a diverse and inclusive workforce. A small subset of their findings include:

     

    1.Whistle Stop Capital and As You Sow researchers reviewed the workforce diversity of 1,641 companies between 2016-2021. Linear regressions found statistically significant positive correlations between increased manager diversity and enterprise value growth rate, free cash flow, return on equity, return on invested capital, and 10-year revenue growth, among other indicators.5

     

    For instance, within the health care sector, statistically significant positive correlations were found between manager diversity and free cash flow per share, income after tax, long-term growth, and 10-year compound annual growth rate. Elevance resides in a sector that has an opportunity to realize a financial benefit with higher amounts of diverse representation within its leadership teams.

     

    _____________________________

     

    2 https://www.sidley.com/en/insights/newsupdates/2023/08/us-supreme-court-ends-affirmative-action-in-higher-education--an-overview-and-practical-next-steps

    3 https://natlawreview.com/article/what-dei-discrimination-latest-eeoc

    4 https://www.eeoc.gov/statutes/title-vii-civil-rights-act-1964

    5 https://www.asyousow.org/report-page/2023-positive-relationships-linking-workforce-diversity-and-financial-performance

     

      3
     

     

         

    2025 Proxy Memo

    Elevance Health In| Shareholder Proposal Requesting a Report on Effectiveness of Efforts to Create a Meritocratic Workplace

     

     

    2.The consultancy BCG found that innovation revenue was 19 percent higher in companies with above-average leadership diversity. In addition, companies with above-average diversity had EBIT margins nine percentage points higher.6

     

    3.A study of the S&P 500 by the Wall Street Journal found that the 20 most diverse companies had an average annual five-year stock return that was 6% higher than the 20 least-diverse companies.7

     

    Benefits of diverse and inclusive teams have been found to include: access to top talent, a better understanding of consumer preferences, a stronger mix of leadership skills, informed strategy discussions, and improved risk management. Diversity and the different perspectives it encourages has also been shown to encourage more creative and innovative workplace environments.8 In contrast, companies where harassment and discrimination exist may experience reduced employee morale and productivity, increased absenteeism, challenges in attracting talent, and difficulties in retaining talent.

     

    Inequality may also threaten the total portfolio return of diversified investors by slowing economic growth: for example, one study determined gender and racial gaps reduced GDP by $2.6 trillion in 2019.9

     

    Unfortunately, corporate initiatives intended to ensure workplace meritocracy vary in quality. Companies must be intentional in ensuring that negative stereotypes and biases against gender, race, or other diversity characteristics do not harm their workplace; and investors must have the data needed to monitor and compare their companies’ effectiveness in meeting this important goal.

     

    Disclosure has not been found to increase legal risk.

     

    Despite concerns raised, hundreds of companies already disclose similar metrics with no evidence of increased legal risk.

     

    As of March 21st, 2025:

    ·84 percent of the S&P 100 release, or have committed to release, their EEO-1 report.
    ·54 percent of the S&P 100 release, or have committed to release, at least one hiring statistic related to gender.
    ·37 percent of the S&P 100 release or have committed to release, at least one hiring statistic related to race/ethnicity.
    ·29 percent of the S&P 100 release or have committed to release, at least one promotion statistic related to gender.
    ·21 percent of the S&P 100 release or have committed to release, at least one promotion statistic related to race/ethnicity.
    ·23 percent of the S&P 100 release or have committed to release, at least one retention or turnover statistic related to gender.
    ·22 percent of the S&P 100 release or have committed to release, at least one retention or turnover statistic related to race/ethnicity.

     

    _____________________________

     

    6 https://www.bcg.com/en-us/publications/2018/how-diverse-leadership-teams-boost-innovation.aspx

    7 https://www.wsj.com/articles/the-business-case-for-more-diversity-11572091200

    8 https://images.forbes.com/forbesinsights/StudyPDFs/Innovation_Through_Diversity.pdf

    9 https://www.frbsf.org/wp-content/uploads/wp2021-11.pdf, p.17

     

      4
     

     

         

    2025 Proxy Memo

    Elevance Health In| Shareholder Proposal Requesting a Report on Effectiveness of Efforts to Create a Meritocratic Workplace

     

     

    As of the filing of this brief, no research reports or media articles were found that indicated any relationship between the publication of these data sets and discrimination lawsuits received by companies. Similarly, no research was found that indicates that the release of the requested data sets impacted outcomes of discrimination lawsuits filed against companies that release their diversity and inclusion data. This absence of evidence is significant because it directly counters a common objection to diversity data disclosure—that transparency about workforce demographics could increase legal vulnerability. Despite hundreds of companies already disclosing this information, there appears to be no documented evidence supporting this concern.

     

    Elevance does not provide transparent quantitative data on the outcomes of its efforts to create a meritocratic workplace.

     

    Disclosing key inclusion factor data – hiring, promotion and retention rates by gender, race and ethnicity categories established by the Equal Employment Opportunity Commission – would allow Elevance’s investors and potential employees to understand the extent to which the company is successfully building, managing, and retaining an effective workforce.

     

    Elevance lags its peers in the disclosure and transparency it provides to investors on the effectiveness of its diversity and inclusion programs. In its statement of opposition, Elevance claims that it “discloses significant workforce composition information for investors and other stakeholders.” However, at the time of this filing, Elevance has only shared its EEO-1 report. Elevance’s failure to disclose hiring rate data of its diverse employees is particularly of concern given that the healthcare sector leads in disclosing hiring rate data of diverse employees.10 Across the Russell 1000 companies, as tracked by As You Sow and Whistle Stop Capital researchers, and as displayed below, since 2020, there has been an upward trend in the release of promotion, hiring, and retention rate disclosure by specific categories.11

     

    _____________________________

     

    10 https://www.asyousow.org/our-work/social-justice/workplace-equity/data-visualization

    11 Indigenous representation data was monitored until 2023.

     

      5
     

     

         

    2025 Proxy Memo

    Elevance Health In| Shareholder Proposal Requesting a Report on Effectiveness of Efforts to Create a Meritocratic Workplace

     

     

     

     

     

     

      6
     

     

         

    2025 Proxy Memo

    Elevance Health In| Shareholder Proposal Requesting a Report on Effectiveness of Efforts to Create a Meritocratic Workplace

     

     

     

     

    Companies in the health sector that release more diversity and inclusion data than Elevance include, but are not limited to Cardinal Health, The Cigna Group, Thermo Fisher Scientific, Illumina, and Humana.

     

    CONCLUSION

     

    Vote “Yes” on this Shareholder Proposal 4. A ‘Yes’ vote supports enhanced transparency by Elevance that addresses a significant disclosure gap. Elevance currently lags healthcare sector peers in providing diversity metrics. The requested data on hiring, promotion, and retention rates will give investors crucial information to evaluate the company’s DEI effectiveness and the likelihood that it will achieve the financial benefits of a diverse workforce.

     

    --

     

    For questions, please contact Meredith Benton, As You Sow, [email protected]

     

    THE FOREGOING INFORMATION MAY BE DISSEMINATED TO SHAREHOLDERS VIA TELEPHONE, U.S. MAIL, E-MAIL, CERTAIN WEBSITES AND CERTAIN SOCIAL MEDIA VENUES, AND SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE OR AS A SOLICITATION OF AUTHORITY TO VOTE YOUR PROXY. THE COST OF DISSEMINATING THE FOREGOING INFORMATION TO SHAREHOLDERS IS BEING BORNE ENTIRELY BY ONE OR MORE OF THE CO-FILERS. PROXY CARDS WILL NOT BE ACCEPTED BY ANY CO-FILER. PLEASE DO NOT SEND YOUR PROXY TO ANY CO-FILER. TO VOTE YOUR PROXY, PLEASE FOLLOW THE INSTRUCTIONS ON YOUR PROXY CARD.

     

     

    7

     

     

     

    Get the next $ELV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELV

    DatePrice TargetRatingAnalyst
    4/15/2025$529.00Outperform → Neutral
    Robert W. Baird
    3/17/2025$450.00Hold → Buy
    Argus
    1/22/2025$520.00 → $440.00Overweight → Equal-Weight
    Stephens
    10/18/2024Buy → Hold
    Argus
    7/18/2024$646.00 → $530.00Buy → Neutral
    BofA Securities
    6/24/2024$643.00Overweight
    Morgan Stanley
    5/30/2024$649.00Outperform
    Robert W. Baird
    3/6/2024$584.00Overweight
    Barclays
    More analyst ratings

    $ELV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Elevance Health Inc.

      SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)

      11/14/24 1:22:35 PM ET
      $ELV
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Elevance Health Inc.

      SC 13G - Elevance Health, Inc. (0001156039) (Subject)

      2/14/24 10:02:59 AM ET
      $ELV
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Elevance Health Inc.

      SC 13G - Elevance Health, Inc. (0001156039) (Subject)

      2/14/23 12:37:59 PM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elevance Health Reports First Quarter 2025 Results

      1Q 2025 operating revenue of $48.8 billion, up 15.4% from 1Q 2024 1Q 2025 adjusted operating gain1 of $3.3 billion, up 4.1% from 1Q 2024 1Q 2025 diluted EPS2 of $9.61; adjusted diluted EPS1 of $11.97 Reaffirm FY 2025 adjusted diluted EPS1 of $34.15 to $34.85 Returned $1.3 billion of capital to shareholders in 1Q 2025 Elevance Health, Inc. (NYSE:ELV) reported first quarter 2025 results. "At Elevance Health, our purpose—to improve the health of humanity—drives everything we do. In the first quarter, we made measurable progress reimagining the healthcare experience with personalized support, real-time digital solutions, and a whole-health model that improves outcomes and reduces co

      4/22/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health to Hold Conference Call and Webcast to Discuss First Quarter 2025 Results on April 22, 2025

      Elevance Health (NYSE:ELV) will release first quarter 2025 financial results on April 22, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 800-396-1242 – No Access Code (Domestic Replay) 203-369-3272 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on April 22, 2025, until the end of the day on May 22, 2025. The call will als

      3/31/25 4:05:00 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Outlook

      4Q 2024 operating revenue of $45.0 billion; FY 2024 of $175.2 billion 4Q 2024 diluted EPS1 of $1.81; adjusted diluted EPS2 of $3.84 FY 2024 diluted EPS1 of $25.68; adjusted diluted EPS2 of $33.04 Projected FY 2025 GAAP diluted EPS1 to be in the range of $30.40 to $31.10 Projected FY 2025 adjusted diluted EPS2 to be in the range of $34.15 to $34.85 Quarterly dividend increased by 5% to $1.71 per share Elevance Health, Inc. (NYSE:ELV) reported fourth quarter and full year 2024 results. "As part of our commitment to elevating whole health and advancing health beyond healthcare, we deliver value to the members and care providers we serve by ensuring simple, affordable, and

      1/23/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Strable-Soethout Deanna D was granted 601 shares, increasing direct ownership by 58% to 1,646 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      5/16/25 4:19:25 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Director Schneider Ryan M. was granted 601 shares, increasing direct ownership by 10% to 6,600 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      5/16/25 4:18:55 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Director Peru Ramiro G was granted 601 shares, increasing direct ownership by 7% to 9,345 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      5/16/25 4:18:24 PM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Leadership Updates

    Live Leadership Updates

    See more

    $ELV
    SEC Filings

    See more

    $ELV
    Financials

    Live finance-specific insights

    See more
    • Elevance Health Appoints Nathan Rich Vice President, Investor Relations

      Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe

      11/4/24 9:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Former Deputy Commissioner of New York State Department of Health Joins Sheppard Mullin

      Nationally Recognized Healthcare Policy Leader Adam Herbst Strengthens the Firm's Regulatory Capabilities for Clients Across the Post-Acute, Aging and Long-Term Care Sectors Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Adam S. Herbst has joined the firm as a healthcare partner in New York. Most recently, Herbst served as the New York State Department of Health's Deputy Commissioner for Aging and Long Term Care. He is the ninth healthcare partner to join the firm in 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030758975/en/Adam Herbst (Photo: Business Wire) In joining Sheppard Mullin's industry-l

      10/30/24 12:55:00 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Performant Financial Corporation Announces the Appointment of Dr. Shantanu Agrawal to Its Board of Directors

      Performant Financial Corporation (NASDAQ:PFMT) (Performant), primarily operating as Performant Healthcare Solutions, a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, is proud to announce the appointment of Dr. Shantanu Agrawal, M.D. to its Board of Directors. Dr. Agrawal brings a wealth of expertise and experience in healthcare policy and payment integrity. As Chief Health Officer at Elevance Health (NYSE:ELV), Dr. Agrawal oversees the whole health strategy, including medical policy and clinical quality, as well as the community health strategy and Elevance Health Foundation. Prior to Elevance Health, Dr. Agrawal held numerous execut

      3/6/24 4:30:00 PM ET
      $ELV
      $PFMT
      Medical Specialities
      Health Care
      Other Consumer Services
      Consumer Discretionary
    • Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Elevance Health, Inc. (0001156039) (Filer)

      5/28/25 6:31:33 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Elevance Health, Inc. (0001156039) (Filer)

      5/14/25 5:27:34 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Elevance Health Inc.

      SCHEDULE 13G/A - Elevance Health, Inc. (0001156039) (Subject)

      5/7/25 10:07:38 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health Reports First Quarter 2025 Results

      1Q 2025 operating revenue of $48.8 billion, up 15.4% from 1Q 2024 1Q 2025 adjusted operating gain1 of $3.3 billion, up 4.1% from 1Q 2024 1Q 2025 diluted EPS2 of $9.61; adjusted diluted EPS1 of $11.97 Reaffirm FY 2025 adjusted diluted EPS1 of $34.15 to $34.85 Returned $1.3 billion of capital to shareholders in 1Q 2025 Elevance Health, Inc. (NYSE:ELV) reported first quarter 2025 results. "At Elevance Health, our purpose—to improve the health of humanity—drives everything we do. In the first quarter, we made measurable progress reimagining the healthcare experience with personalized support, real-time digital solutions, and a whole-health model that improves outcomes and reduces co

      4/22/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health to Hold Conference Call and Webcast to Discuss First Quarter 2025 Results on April 22, 2025

      Elevance Health (NYSE:ELV) will release first quarter 2025 financial results on April 22, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 800-396-1242 – No Access Code (Domestic Replay) 203-369-3272 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on April 22, 2025, until the end of the day on May 22, 2025. The call will als

      3/31/25 4:05:00 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Outlook

      4Q 2024 operating revenue of $45.0 billion; FY 2024 of $175.2 billion 4Q 2024 diluted EPS1 of $1.81; adjusted diluted EPS2 of $3.84 FY 2024 diluted EPS1 of $25.68; adjusted diluted EPS2 of $33.04 Projected FY 2025 GAAP diluted EPS1 to be in the range of $30.40 to $31.10 Projected FY 2025 adjusted diluted EPS2 to be in the range of $34.15 to $34.85 Quarterly dividend increased by 5% to $1.71 per share Elevance Health, Inc. (NYSE:ELV) reported fourth quarter and full year 2024 results. "As part of our commitment to elevating whole health and advancing health beyond healthcare, we deliver value to the members and care providers we serve by ensuring simple, affordable, and

      1/23/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Elevance Health downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Elevance Health from Outperform to Neutral and set a new price target of $529.00

      4/15/25 9:24:40 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health upgraded by Argus with a new price target

      Argus upgraded Elevance Health from Hold to Buy and set a new price target of $450.00

      3/17/25 8:22:06 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health downgraded by Stephens with a new price target

      Stephens downgraded Elevance Health from Overweight to Equal-Weight and set a new price target of $440.00 from $520.00 previously

      1/22/25 7:37:04 AM ET
      $ELV
      Medical Specialities
      Health Care